What’s Oncosec Medical (NASDAQ:ONCS) Upside After This Short Interest Increase?

February 17, 2018 - By Nellie Frank

 What's Oncosec Medical (NASDAQ:ONCS) Upside After This Short Interest Increase?

The stock of Oncosec Medical (NASDAQ:ONCS) registered an increase of 1.83% in short interest. ONCS’s total short interest was 1.84 million shares in February as published by FINRA. Its up 1.83% from 1.81M shares, reported previously. With 1.09 million shares average volume, it will take short sellers 2 days to cover their ONCS’s short positions. The short interest to Oncosec Medical’s float is 9.73%.

The stock decreased 6.94% or $0.14 during the last trading session, reaching $1.81. About 1.29 million shares traded or 39.90% up from the average. OncoSec Medical Incorporated (NASDAQ:ONCS) has declined 34.57% since February 17, 2017 and is downtrending. It has underperformed by 51.27% the S&P500.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. The company has market cap of $77.72 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. It currently has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

OncoSec Medical Incorporated (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 10 analyst reports since March 9, 2016 according to SRatingsIntel. Maxim Group maintained OncoSec Medical Incorporated (NASDAQ:ONCS) rating on Thursday, June 8. Maxim Group has “Buy” rating and $500 target. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, March 9. The firm earned “Buy” rating on Monday, June 12 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Friday, January 19. The stock of OncoSec Medical Incorporated (NASDAQ:ONCS) has “Buy” rating given on Friday, June 2 by Maxim Group. The rating was maintained by Noble Financial on Tuesday, June 13 with “Buy”. The firm earned “Buy” rating on Thursday, July 21 by Rodman & Renshaw. The firm has “Buy” rating given on Friday, June 2 by H.C. Wainwright. On Thursday, November 9 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Friday, December 15.

More notable recent OncoSec Medical Incorporated (NASDAQ:ONCS) news were published by: Prnewswire.com which released: “OncoSec Receives $9.3 Million Warrant Exercise” on November 13, 2017, also Prnewswire.com with their article: “This Morning’s Technical Outlook on Biotech Stocks — NewLink Genetics, OHR …” published on February 15, 2018, Marketwatch.com published: “OncoSec Medical Inc.” on May 10, 2017. More interesting news about OncoSec Medical Incorporated (NASDAQ:ONCS) were released by: Prnewswire.com and their article: “OncoSec Medical Incorporated Announces Closing of $23.0 Million Public …” published on February 06, 2018 as well as Prnewswire.com‘s news article titled: “OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock” with publication date: January 31, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: